Genmab CEO hopes for verdict in Johnson & Johnson arbitration soon
Jan van de Winkel, CEO of Genmab, hopes for a fast decision in the arbitration dispute, which concerns Darzalex royalties, with Johnson & Johnson-owned Janssen.
by marketwire, trranslated by daniel pedersen
Genmab hopes to soon see a verdict in the large and potentially costly arbitration dispute with partner Johnson & Johnson concerning the rights to the huge revenue inflows from cancer drug Darzalex.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab sales of Darzalex exceed expectations in Q3
For subscribers
Genmab: Janssen dispute cost DKK 146m in H1
For subscribers
.jpg&w=384&q=75)
